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Background: Single-cell network profiling (SCNP) is a multi-parametric flow cytometry-based approach that
simultaneously measures basal and modulated intracellular signaling activity in multiple cell subpopulations.
Previously, SCNP analysis of a broad panel of immune signaling pathways in cell subsets within PBMCs from 60
healthy donors identified a race-associated difference in B cell anti-IgD-induced PI3K pathway activity.
Methods: The present study extended this analysis to a broader range of signaling pathway components
downstream of the B cell receptor (BCR) in European Americans and African Americans using a subset of donors
from the previously analyzed cohort of 60 healthy donors. Seven BCR signaling nodes (a node is defined as a paired
modulator and intracellular readout) were measured at multiple time points by SCNP in PBMCs from 10 healthy
donors [5 African Americans (36-51 yrs), 5 European Americans (36-56 yrs), all males].
Results: Analysis of BCR signaling activity in European American and African American PBMC samples revealed that,
compared to the European American donors, B cells from African Americans had lower anti-IgD induced
phosphorylation of multiple BCR pathway components, including the membrane proximal proteins Syk and SFK as
well as proteins in the PI3K pathway (S6 and Akt), the MAPK pathways (Erk and p38), and the NF-κB pathway (NF-
κB). In addition to differences in the magnitude of anti-IgD-induced pathway activation, racial differences in BCR
signaling kinetic profiles were observed. Further, the frequency of IgD+ B cells differed by race and strongly
correlated with BCR pathway activation. Thus, the race-related difference in BCR pathway activation appears to be
attributable at least in part to a race-associated difference in IgD+ B cell frequencies.
Conclusions: SCNP analysis enabled the identification of statistically significant race-associated differences in BCR
pathway activation within PBMC samples from healthy donors. Understanding race-associated contrasts in immune
cell signaling responses may be one critical component for elucidation of differences in immune-mediated disease
prevalence and treatment responses.
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Racial differences have been documented in the preva-
lence of autoimmune diseases such as systemic lupus
erythematosus [1] and multiple sclerosis [2] and in the
clinical response to immunotherapies [such as IFN-α
[3] and Benlysta/belimumab [4]]. However, the biologic
basis for such race-associated differences remains
poorly understood. A better understanding of the* Correspondence: diane.longo@nodality.com
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reproduction in any medium, provided the orunderlying biologic mechanisms of race-associated dif-
ferences in immune signaling responses may provide
clinically relevant information regarding the mechan-
isms underlying race-related differences in treatment
responsiveness.
Single-cell network profiling (SCNP) is a multipara-
metric flow cytometry-based approach that enables the
simultaneous measurement of basal and evoked signaling
in multiple cell subpopulations [5]. Recently, SCNP tech-
nology was applied to quantify immune signaling path-
way activation following modulation with 12
immunomodulators (including IFN-α, IFN-γ, IL-2, IL-4,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of donor numbers, age, race, and
gender
AA EA
No. of Donors 5 5
Mean Age (y) 45.4 48.6
Age Range (y) 36-51 36-56
Gender 5 Male 5 Male
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CD40L) in 7 distinct immune cell subpopulations within
PBMC samples from 60 healthy donors [6]. Using a
training/test set approach, race-associated differences in
anti-IgD-induced levels of p-S6 and p-Akt in B cells were
identified [6]. The present study was performed to
analyze anti-IgD-induced modulation of a broader range
of BCR signaling pathway components at multiple time
points using a subset of European American (EA) and
African American (AA) donor samples from the previ-
ously analyzed healthy donor cohort [7].
Methods
PBMC samples
Cryopreserved PBMC samples collected from 10 healthy
donors [5 AAs (mean age 45.4 yrs), 5 EAs (mean age
48.6 yrs), all males (Table 1)] within the Department of
Transfusion Medicine, Clinical Center, National Insti-
tutes of Health with Institutional Review Board approval
were used in this study. All blood samples, donated for
research purposes with informed consent, were collected
and processed as described previously [8].
SCNP assay
Cryopreserved PBMC samples were thawed at 37°C and
resuspended in RPMI 1640 (1% FBS) before staining with
amine aqua viability dye (Invitrogen, Carlsbad, CA). Cells
were resuspended in RPMI 1640 (10% FBS), aliquoted toFigure 1 Gating strategy used to delineate the viable B cell subpopul
were amine aqua negative, lymphocytes by light scatter, positive for CD20,100,000 cells per well in 96-well plates, and rested for
2 h at 37°C prior to incubation with anti-IgD 5 μg/ml
(BD, San Jose, CA) or anti-IgM 10 μg/ml (Southern Bio-
tech, Birmingham, AL). After modulation with anti-IgD
(for 5′, 15′, 30′, or 60′) or anti-IgM (5′), cells were fixed
with paraformaldehyde and permeabilized with 100%
ice-cold methanol as previously described [9]. Permeabi-
lized cells were washed with FACS buffer (PBS, 0.5%
BSA, 0.05% NaN3), pelleted, and stained with fluoro-
chrome-conjugated Abs. Abs used include anti-CD20
(clone H1), -p-NF-κB (clone K10-895.12.50), -c-poly
(ADP-ribose) polymerase (clone F21-852), -p-Erk (clone
20A), -p-SFK/Lck (clone 4/LckY505), -p-p38 (clone 36/
p38), -p-Syk (clone 17a/P-ZAP70) [BD, San Jose CA]; -p-
Akt (clone D9E), -p-S6 (clone 2F9) [CST, Danvers, MA];
and -IgD [Southern Biotech, Birmingham, AL].
Flow cytometry data acquisition and analysis
Flow cytometry data was acquired using FACS DIVA
software (BD, San Jose, CA) on an LSRII Flow Cytometer
(BD, San Jose, CA). All flow cytometry data were ana-
lyzed with WinList (Verity House Software, Topsham,
ME). For all analyses, dead cells and debris were
excluded by forward scatter (FSC), side scatter (SSC),
and amine aqua viability dye. Viable B cells were deli-
neated according to the gating scheme shown in
Figure 1.
SCNP terminology and metrics
The term “signaling node” refers to a specific protein
readout in the presence or absence of a specific modula-
tor. For example, the response to anti-IgD stimulation
can be measured using p-S6 as a readout. This signaling
node is designated “anti-IgD! p-S6”. The “Fold” metric
was applied to measure the level of anti-IgD-induced
modulation of each signaling molecule after modulation
compared to its level in the basal state. The “Fold” metrication within PBMCs. Boolean logic was used to identify cells that
and negative for c-poly(ADP-ribose) polymerase (c-PARP).
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Fold : log2 MFI Modulatedð Þ=MFI Unmodulatedð Þ½ ð Þ
Where MFI is the median fluorescence intensity.
Statistical analyses
Statistical differences between groups were assessed by
the Wilcoxon rank sum test. For each of the 7 phospho-
protein readouts, race-associated differences were
assessed by averaging the Fold values over the 4 modu-
lated time points (5’, 15’, 30’, 60’) and applying the Wil-
coxon rank sum test to the averaged Fold value. One
donor was excluded from all analyses due to an insuffi-
cient number (<200) of B cells (“events”) collected by the
flow cytometer.
Correlations between signaling nodes
R software (version 2.12.1) was used to compute Pearson
correlation coefficients between IgD+ B cell frequency
and BCR signaling nodes. Heatmaps were generated in
Excel 2007 (Microsoft, Redmond, WA).Figure 2 BCR signaling activation in AA and EA donors. A, Fold vs. time
donors (one AA donor was excluded due to an insufficient number of B ce
were assessed by the Wilcoxon rank sum test (see Materials and Methods).
associated difference (p< 0.05).Results and discussion
Seven signaling nodes (anti-IgD! p-S6, anti-IgD! p-
Syk, anti-IgD! p-Akt, anti-IgD! p-Erk, anti-IgD! p-
SFK, anti-IgD! p-p38, and anti-IgD! p-NF-κB), or
specific protein readouts of modulated signaling, were
measured in viable B cells (defined as amine aqua nega-
tive, forward scatter/side scatter low, CD20+, c-poly
(ADP-ribose) polymerase (c-PARP) negative cells, Fig-
ure 1) at several time points following modulation with
anti-IgD in PBMCs collected from 10 healthy donors
(Table 1). The “Fold” metric (see Materials and Meth-
ods) was applied to measure the level of a signaling
molecule after modulation compared to its level in the
basal state.
Averaged over all donors, viable B cells constituted
18.3% (standard deviation = 8.8%, range = 2.2–28.1%) of
the parental Lymphocyte subpopulation (see Figure 1).
For one donor, the CD20+ B cell percentage was ex-
tremely low (2.2% of Lymphocytes) resulting in too few
B cells for analysis (i.e. <200 B cells in most wells of
the 96-well plate). Therefore, data for this donor was
excluded from the analysis presented below.is shown for the 7 phospho-protein readouts for 9 of the 10 healthy
lls (<200 events) collected for analysis). B, Race-associated differences
Four phospho-protein readouts had a statistically significant race-
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activation
On average, compared with B cells from EA donors,
B cells from AA donors displayed lower anti-IgD-
induced phosphorylation for all 7 of the tested BCR
pathway components (Figure 2A). For the p-Syk, p-
S6, p-Akt, and p-Erk signaling readouts, the race-
associated difference in the magnitude of anti-IgD-
induced activation levels (quantified by the Fold and
averaged over all time points, see Materials and
Methods) reached statistical significance (p< 0.05,
Wilcoxon test, Figure 2B). To assess whether or not
the race-associated difference in BCR pathway activa-
tion is specific to modulation with anti-IgD, the 7
phospho-proteins were measured following modula-
tion with anti-IgM (5′) and higher induced phos-
phorylation was observed in EA donors than in AA
donors, reaching statistical significance (p< 0.05,
Wilcoxon test) for p-Syk, p-S6, p-Akt, and p-SFK
(data not shown). Future studies will be performed
in larger independent donor cohorts with greater
statistical power to assess the external validity of the
race-associated differences observed in this explora-
tory study.Figure 3 IgD+ B cell percentages in AA and EA donors. CD20- lymphoc
region for each donor. The IgD+ region was applied to the viable B cell sub
Representative flow plots from one healthy donor are shown. IgD+ B cell p
a higher percentage of IgD+ B cells than AAs and the race-associated differBCR signaling kinetics in AA and EA donors
For the BCR signaling pathway components p-SFK, p-
p38, and p-NF-κB, a rapid, transient increase in signal
was observed, peaking at the 5 minute time point fol-
lowed by a steady decrease until the 60 minute time
point. For these three BCR signaling components, the
kinetic profiles were comparable between AA and EA
donors. Previous studies have reported similar kinetic
profiles for p-p38 in human CD20+ B cells following
BCR cross-linking with anti-IgM and anti-IgG [10].
In contrast, anti-IgD-induced signaling kinetics for p-
Syk, p-Akt, and p-S6 appeared different among EA and
AA donors (Figure 2A). Specifically, increases for both
p-Syk and p-Akt were at or near peak values at 5 min-
utes and, in EA donors, gradually declined through the
60 minute time point [with an average difference in the
Fold between the 5′and 60′ time point of 0.25 (for p-
Syk) and 0.32 (for p-Akt)], while peak levels (although
lower in magnitude) were generally sustained through
the 60 minute time point in AA donors [with an aver-
age difference in the Fold between the 5’ and 60’ time
point of −0.04 (for p-Syk) and 0.11 (for p-Akt)]. In re-
cent analyses using B cells from healthy donors, anti-
IgM/anti-IgG-induced Syk phosphorylation was reportedytes were used as an internal negative control to define the IgD+
population to determine the IgD+ B cell percentage for each donor.
ercentages were assessed under the unmodulated condition. EAs had
ence was significant (p = 0.016, Wilcoxon test).
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levels by 90 minutes [10] thus displaying a signaling
kinetic profile similar to the p-Syk profile observed here
for EA donors.
For anti-IgD-induced p-S6, peak activity was
observed at 15 minutes (i.e. delayed relative to more
upstream pathway components p-Akt and p-Syk)
and, in EA donors, the p-S6 levels were sustained
through the 60 minute time point (with an average
difference in the Fold between the 15’ and 60’ time
point of 0.02), while p-S6 levels had declined by the
60 minute time point in AA donors (with an average
difference in the Fold between the 15’ and 60’ time
point of 0.98).
To assess BCR signaling responses at a network
level, Pearson correlation coefficients between pairs
of signaling nodes at each time point were calcu-
lated. All of the responses at the 5’ time point were
positively correlated (r> 0.6), and positive correla-
tions were observed between the majority of the
nodes at later time points (i.e. 15’, 30’, and 60’) with
the exception of the node-to-node correlations with
p-NF-κB or p-SFK, nodes which displayed low or no
induced activation (average Folds< 0.3) at later time
points (Figure 2A).Figure 4 Correlations between IgD+ B cell percentages and BCR signa
Pearson correlation coefficients (r) between the IgD+ B cell percentage and
point.Race-associated differences in IgD+B cell percentages
Given that race-associated differences in anti-IgD
responses were observed in the overall viable B cell
population, it is of interest to determine if the race-asso-
ciated difference in anti-IgD responses is due to a race-
associated difference in anti-IgD responses specifically
within the IgD+ B cell subpopulation and/or due to a
race-associated difference in the frequency of IgD+ B
cells. Although it would be ideal to measure anti-IgD
responses directly within IgD+ B cells, modulation with
anti-IgD can interfere with the subsequent detection of
surface IgD with fluorescently-labeled anti-IgD. There-
fore, an indirect approach was taken whereby the IgD+ B
cell frequency was determined in the unmodulated con-
dition and the relationship between IgD+ B cell frequen-
cies and anti-IgD responses within the overall viable B
cell population was assessed.
The percentage of IgD+ B cells was determined for
each donor by using the CD20- Lymphocyte subpopula-
tion within each donor PBMC sample as an internal
negative control to define an IgD+ region which was
subsequently applied to the viable B cell subpopulation
(Figure 3). The percentage of IgD+ B cells was signifi-
cantly lower in AA donor samples than in EA donor
samples (p = 0.016, Wilcoxon test). Despite a significantling pathway activation. The heatmap shows the magnitude of the
the Fold for each signaling node at each anti-IgD modulation time
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cells, the level of IgD expression within the IgD+ B cell
subset (as quantified by the median fluorescence inten-
sity (MFI) of IgD in the IgD+ B cell subset) did not differ
between the races (p = 0.286, Wilcoxon test).
The correlation between IgD+ B cell frequency and
BCR signaling pathway activation was then assessed by
calculating the Pearson correlation coefficient, r, between
IgD+ B cell percentage and the Fold metric for each
BCR signaling node at each anti-IgD modulation time
point (Figure 4). A positive correlation (defined as r
> 0.6) was observed for the majority of BCR signaling
responses measured, with the exception of p-NF-κB and
p-SFK at the 15’, 30’, and 60’, [low or no induced activa-
tion (average Folds< 0.3) was observed for these nodes
at these time points (see Figure 2A)].
For the anti-IgD induced p-S6 response at the 15’ time
point, pronounced bimodality was observed allowing for
a quantitative assessment of the percentage of p-S6 “high”
(i.e. anti-IgD responsive B cells). The percentage of anti-
IgD responsive B cells closely approximated the percent-
age of IgD+ B cells for each donor (Figure 5). While the
percentage of p-S6 “high” cells was significantly different
between the two racial groups (p = 0.016, Wilcoxon test),
the ratio of the MFI in the p-S6 “high” region to the MFIFigure 5 IgD+ B cell percentage vs. percentage of anti-IgD responsive
for 2 representative donors. p-S6 “high” and p-S6 “low” regions were establ
for one donor and the same regions were applied to all donors. The perce
significant race-associated difference (p = 0.016, Wilcoxon test). The ratio of
did not differ between the races (p = 0.905, Wilcoxon test).in the p-S6 “low” region did not differ between the races
(p = 0.905, Wilcoxon test).
Overall, these results suggest that the observed race-
associated difference in BCR signaling pathway activation
could be attributed at least in part to a race-associated
difference in IgD+ B cell frequencies (and thus the per-
centage of B cells that respond to anti-IgD) and not to
surface levels of IgD or intrinsic differences in the magni-
tude of the anti-IgD induced response within each B cell.
Within the peripheral blood, the IgD+ B cell subpopu-
lation consists of naïve (CD27-) B cells and non-switched
(IgE-/IgG-/IgA-) memory (CD27+) B cells, while the
IgD- B cell subpopulation consists primarily of switched
(IgE+/IgG+/IgA+) memory (CD27+) B cells [11,12].
Thus, in the donor set studied here, AAs may have a
greater frequency of switched memory B cells than EA
donors. Studies which include additional B cell pheno-
typic markers, such as CD27 and IgM, are currently
underway to assess race-related differences in more well-
defined B cell subsets. To our knowledge, no prior stud-
ies have reported race-associated differences in B cell
subset frequencies. However, changes in the composition
of the peripheral B cell pool have been reported for sys-
temic lupus erythematosus [13], common variable im-
munodeficiency [14], and with age [15].(p-S6 “high”) B cells. Anti-IgD-induced p-S6 histograms are shown
ished by estimating the location of the trough in the bimodal profile
ntage of anti-IgD induced p-S6 “high” B cells had a statistically
the MFI in the p-S6 “high” region to the MFI in the p-S6 “low” region
Longo et al. Journal of Translational Medicine 2012, 10:113 Page 7 of 7
http://www.translational-medicine.com/content/10/1/113Establishing the range of BCR signaling responses in
healthy donors can enable the identification of dysregu-
lated signaling in disease states by providing a reference
range to which signaling responses from diseased samples
can be compared. Recently, BCR signaling profiles from
follicular lymphoma B cells were compared with signaling
profiles from B cells from healthy blood donors to iden-
tify alterations in BCR-mediated signaling in follicular
lymphoma, and BCR-mediated phosphorylation of p38
was found to be lower in follicular lymphoma than in a
reference healthy blood donor [16]. The data presented
here demonstrating that BCR-mediated signaling within
healthy donors can vary with at least one demographic
variable (race) highlights the importance of using healthy
donor cohorts consisting of individuals matched to the
diseased population by demographic characteristics such
as age, race, and gender. Such criteria may be critical in
establishing reference signaling ranges as a basis for com-
parison with diseased signaling responses.Conclusions
In this study, differences in B cell subset frequencies and
BCR-mediated signaling pathway activation were found
amongst AA and EA donors. Subsequent studies will ex-
tend the SCNP approach used here to assess differences
in B cell subpopulation frequencies and BCR signaling in
additional ethnic groups. Controlling for ethnicity is
emerging as a key component in assuring the accuracy of
clinical diagnostics [17] and in selecting treatments [4].
Ultimately, a greater understanding of race-associated
differences in immune cell signaling responses may help
to elucidate the basis for racial differences in immune-
mediated disease prevalence and treatment response
rates.
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